ATE534379T1 - Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen - Google Patents

Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen

Info

Publication number
ATE534379T1
ATE534379T1 AT06776964T AT06776964T ATE534379T1 AT E534379 T1 ATE534379 T1 AT E534379T1 AT 06776964 T AT06776964 T AT 06776964T AT 06776964 T AT06776964 T AT 06776964T AT E534379 T1 ATE534379 T1 AT E534379T1
Authority
AT
Austria
Prior art keywords
peptide compounds
new use
muscle pain
treat muscle
treat
Prior art date
Application number
AT06776964T
Other languages
English (en)
Inventor
Bettina Beyreuther
Thomas Stoehr
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Application granted granted Critical
Publication of ATE534379T1 publication Critical patent/ATE534379T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT06776964T 2005-08-18 2006-08-18 Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen ATE534379T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05017977A EP1754476A1 (de) 2005-08-18 2005-08-18 Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US81185906P 2006-06-08 2006-06-08
US81184006P 2006-06-08 2006-06-08
PCT/EP2006/008171 WO2007020103A2 (en) 2005-08-18 2006-08-18 Novel use of peptide compounds for treating muscle pain

Publications (1)

Publication Number Publication Date
ATE534379T1 true ATE534379T1 (de) 2011-12-15

Family

ID=35429313

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06776964T ATE534379T1 (de) 2005-08-18 2006-08-18 Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen

Country Status (15)

Country Link
US (2) US20080280835A1 (de)
EP (3) EP1754476A1 (de)
JP (1) JP2009504703A (de)
CN (1) CN101242821A (de)
AR (1) AR056467A1 (de)
AT (1) ATE534379T1 (de)
AU (1) AU2006281591A1 (de)
BR (1) BRPI0614794A2 (de)
CA (1) CA2619545A1 (de)
EA (1) EA014496B1 (de)
ES (1) ES2378244T3 (de)
MX (1) MX2008002293A (de)
TW (1) TW200800147A (de)
WO (1) WO2007020103A2 (de)
ZA (1) ZA200801253B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DE60100055T2 (de) * 2001-03-21 2003-07-24 Sanol Arznei Schwarz Gmbh Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
EA013590B1 (ru) * 2003-12-02 2010-06-30 Шварц Фарма Аг Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1734980A1 (de) * 2004-04-16 2006-12-27 Schwarz Pharma Ag Verwendung peptidähnlicher verbindungen zur vorbeugung und behandlung chronischer kopfschmerzen
EP1604655A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
EP1920780A1 (de) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptidverbindungen zur Behandlung von Krankheiten mit erhöhter Erregbarkeit
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP2037965B1 (de) 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmazeutische zusammensetzung mit synergistischer antikonvulsiver wirkung
US8450336B2 (en) * 2006-12-14 2013-05-28 Nps Pharmaceuticals, Inc Use of D-serine derivatives for the treatment of anxiety disorders
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
WO2010148300A1 (en) * 2009-06-19 2010-12-23 The University Of North Carolina At Chapel Hill Methods of treatment of neurological disorders
CA2774569A1 (en) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
EP2496228B1 (de) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Verfahren zur behandlung von aufmerksamkeitsdefizitstörung mit hyperaktivität
US8927602B2 (en) * 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
JP5699030B2 (ja) * 2010-07-05 2015-04-08 Ａｘｉｓ株式会社 エタネルセプトを含む線維筋痛症の治療剤
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid
NZ610701A (en) 2010-12-02 2015-06-26 Ucb Pharma Gmbh Once daily formulation of lacosamide
JP5855770B2 (ja) * 2012-02-06 2016-02-09 プリジェン，ウィリアム，エル． ファムシクロビルとセレコキシブとの組合せを含む、機能性身体症候群のための抗ウイルス化合物とｃｏｘ−２インヒビターとの組合せ療法
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
WO2023244864A1 (en) * 2022-06-17 2023-12-21 Spencer Spence Ozone therapeutic treatment apparatus and method of use to treat a treatment location

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) * 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) * 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
HUT77282A (hu) * 1994-10-05 1998-03-30 Darwin Discovery Limited Peptidvegyületek és gyógyászati alkalmazásuk metalloproteáz inhibitorokként
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
WO1997003677A1 (en) * 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US6114390A (en) * 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
KR100491282B1 (ko) * 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6048899A (en) * 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
JP4213339B2 (ja) * 1997-07-15 2009-01-21 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド 発作を治療するのに有用なアミノ酸誘導体
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6492553B1 (en) * 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
ATE449603T1 (de) * 1998-09-15 2009-12-15 Lilly Co Eli Verwendung von duloxetine zur behandlung von fibromyalgie
NZ518901A (en) * 1999-12-01 2004-08-27 Ucb S A levetiracetam alone or in combination with a compound inducing neural inhibition mediated by the GABA receptors for treatment of chronic pain, bipolar disorder, mania and migraine
SI1311256T1 (sl) * 2000-08-17 2005-12-31 Teva Pharma Uporaba derivatov amidov valprojske kisline in amidov 2-valproenske kisline za zdravljenje ali preprecevanje bolecin in/ali glavobolnih motenj
DK1486206T3 (da) * 2000-08-25 2008-02-11 Res Corp Technologies Inc Anvendelse af antikonvulsiv aminosyre til behandling af bipolære sygdomme
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DE60100055T2 (de) 2001-03-21 2003-07-24 Sanol Arznei Schwarz Gmbh Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
RU2337682C2 (ru) * 2002-11-01 2008-11-10 Такеда Фармасьютикал Компани Лимитед Средство для профилактики или лечения невропатии
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
EP1625378A4 (de) * 2002-12-03 2007-05-16 Ucb Sa VERFAHREN ZUR IDENTIFIZIERUNG VONAGENTIEN ZUR BEHANDLUNG VON ANFûLLEN, NEUROLOGISCHEN ERKRANKUNGEN,ENDOKRINOPATHIEN UND HORMONKRANKHEITEN
MXPA05006802A (es) * 2002-12-19 2005-09-08 Pharmacia Corp Formulacion no higroscopica que comprende un farmaco higroscopico.
JP2006515326A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
US7320675B2 (en) * 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
EA013590B1 (ru) * 2003-12-02 2010-06-30 Шварц Фарма Аг Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
EP1734980A1 (de) * 2004-04-16 2006-12-27 Schwarz Pharma Ag Verwendung peptidähnlicher verbindungen zur vorbeugung und behandlung chronischer kopfschmerzen
WO2005110405A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
EP1604654A1 (de) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
EP1604656A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20080096872A1 (en) * 2004-12-22 2008-04-24 Friedman Robert S Composition for Treatment of Pain Specification
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP2037965B1 (de) * 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmazeutische zusammensetzung mit synergistischer antikonvulsiver wirkung
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
US20100260716A1 (en) * 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions

Also Published As

Publication number Publication date
EP1915140A2 (de) 2008-04-30
US20080280835A1 (en) 2008-11-13
JP2009504703A (ja) 2009-02-05
AR056467A1 (es) 2007-10-10
US20070197657A1 (en) 2007-08-23
WO2007020103A2 (en) 2007-02-22
AU2006281591A1 (en) 2007-02-22
TW200800147A (en) 2008-01-01
MX2008002293A (es) 2008-03-14
CN101242821A (zh) 2008-08-13
EP2308482A1 (de) 2011-04-13
WO2007020103A3 (en) 2007-06-07
EA200800614A1 (ru) 2008-06-30
BRPI0614794A2 (pt) 2011-04-12
ZA200801253B (en) 2008-12-31
CA2619545A1 (en) 2007-02-22
ES2378244T3 (es) 2012-04-10
EP1754476A1 (de) 2007-02-21
EA014496B1 (ru) 2010-12-30
EP1915140B1 (de) 2011-11-23

Similar Documents

Publication Publication Date Title
ATE534379T1 (de) Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen
ATE446092T1 (de) Verwendung von oxycodon zur behandlung von viszeralem schmerz
ATE521352T1 (de) Verwendung von flibanserin zur behandlung von prämenopausalen störungen der sexuellen lust
ATE471717T1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE419856T1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
ATE525372T1 (de) Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen
DE502006007982D1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
ATE483460T1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE509621T1 (de) Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen
DE602005015297D1 (de) Verwendung von ozon zur verbesserung des knetvorgangs
ATE526982T1 (de) Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602007009877D1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602005013287D1 (de) Zusammensetzung zur behandlung von leder
ATE504307T1 (de) Verwendung von gallium (iii) komplexen zur behandlung von melanomen
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen